Our latest articles
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
The approval is good for CSL, and better for Uniqure.
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
As the company pulls Blenrep, questions about its future will only intensify.